Abstract: A method for assessing drug-resistant Klebsiella pneumoniae includes the following steps. A test sample is provided, wherein the test sample includes a Klebsiella pneumoniae. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Klebsiella pneumoniae is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Klebsiella pneumoniae is resistant to a carbapenem antibiotic or a colistin or not. When the Klebsiella pneumoniae is resistant to the carbapenem antibiotic, the target mass spectrum data includes a first anti-carbapenem feature mark, and when the Klebsiella pneumoniae is resistant to the colistin, the target mass spectrum data includes a first anti-colistin feature mark.

Abstract: The present invention relates to a probe for detecting Mycobacterium tuberculosis complex (MTBC) and Mycobacterium tuberculosis (MTB) from clinical specimens. The method mainly comprised two steps: (1) amplifying a target DNA of the clinical specimens through nested PCR; and (2) hybridizing to the target DNA with a gold nanoparticle probe. The presence of MTB or MTBC was detected after the absorbance at 525 nm was determined with a spectrophotometer during hybridization at a defined time. Direct observation on color changes can also be detected after a longer incubating time. The merits of this assay include being easy to operate, sophisticated detection equipment is not necessary, low cost, time saving, and, high sensitivity and specificity.